Cimifugin

Research use only, not for human use.

Cimifugin inhibits NO production induced by lipopolysaccharide in macrophage cell line RAW 264.7 and for 1, 1-diphenyl-2-picrylhydrazyl free-radical scavenging activity in cell-free bioassay system.

Cimifugin inhibits NO production induced by lipopolysaccharide in macrophage cell line RAW 264.7 and for 1, 1-diphenyl-2-picrylhydrazyl free-radical scavenging activity in cell-free bioassay system.(In Vitro):The effect of Cimifugin (Cimitin) on TSLP decreases significantly when expression of CLDN1 is interfered with siRNA and this implied Cimifugin inhibits initiative cytokines through restoring TJs.(In Vivo):Cimifugin (Cimitin; 12.5 or 50 mg/kg/day; intragastrically; 2 days) significantly inhibits TSLP and IL-33 in the initial stage of Mice are sensitized and challenged with FITC to establish type 2 atopic dermatitis (AD) model. Simultaneously, Cimifugin reduces the separated gap among the epithelial cells and increased the expression of TJs.

The effect of Cimifugin (Cimitin) on TSLP decreases significantly when expression of CLDN1 is interfered with siRNA and this implied Cimifugin inhibits initiative cytokines through restoring TJs.

Cimifugin (Cimitin; 12.5 or 50 mg/kg/day; intragastrically; 2 days) significantly inhibits TSLP and IL-33 in the initial stage of Mice are sensitized and challenged with FITC to establish type 2 atopic dermatitis (AD) model. Simultaneously, Cimifugin reduces the separated gap among the epithelial cells and increased the expression of TJs.

Cimitin

Others

Other Targets

Others

Inflammation/Immunology

——

37921-38-3

306.3

C16H18O6

>98% (HPLC)

DMSO : ≥ 3.1 mg/mL; 10.12 mM

CC(C)([C@@H]1Cc2c(O1)cc1c(c2OC)c(=O)cc(o1)CO)O

——

(-20℃)

With Ice Pack

≥ 2 years